AtaiBeckley (ATAI) Non-Current Assets (2022 - 2026)

AtaiBeckley's (ATAI) quarterly Non-Current Assets came in at $409000.0 in Q1 2026.

AtaiBeckley (ATAI) Non-Current Assets (2022 - 2026) Analysis & Trends

AtaiBeckley (ATAI) has 4 years of Non-Current Assets data on file, last reported at $409000.0 in Q3 2025.

For the quarter ending Q3 2025, Non-Current Assets rose 100.36% year-over-year to $409000.0; the trailing twelve-month figure through Sep 2025 stood at $409000.0 (changed N/A YoY), and the FY2022 full-year result was $5.6 million, changed N/A from the prior year.
Non-Current Assets steadied at $409000.0 in Q1 2026 per ATAI's latest filing.
In the past five years, Non-Current Assets ranged from a high of $151.6 million in Q1 2024 to a low of -$114.1 million in Q3 2024.
A 4-year average of $15.8 million and a median of $5.5 million in 2022 frame the typical range for Non-Current Assets.
Peak annual rise in Non-Current Assets reached 2664.79% in 2024, while the deepest fall reached 901.81% in 2024.
Tracing ATAI's Non-Current Assets over 4 years: stood at $5.6 million in 2022, then surged by 152.12% to $14.2 million in 2023, then sank by 901.81% to -$114.1 million in 2024, then jumped by 100.36% to $409000.0 in 2025.
Business Quant data shows ATAI's Non-Current Assets at $409000.0 in Q3 2025, $409000.0 in Q2 2025, and $409000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Assets (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	21.65 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	5.83 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	1.95 Bn
4	NuCana	279.75 Bn	279.75 Bn	-	3.95 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	14.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	22.66 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	289.41 Mn
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.96 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	285.82 Mn
10	AtaiBeckley	2.56 Bn	2.56 Bn	-	409,000.00

Download Data